Loading
NASDAQHealthcareBiotechnology
Latest quote
$5.01
−$0.07 · -1.38%
Abeona Therapeutics Inc. is a biopharmaceutical company in the clinical development stage, focused on creating innovative gene and cell therapies to address severe and uncommon genetic diseases. Its leading program, EB-101, an autologous gene-corrected cell therapy, is presently in a Phase III clinical trial for treating recessive dystrophic epidermolysis bullosa. The company's pipeline also features several other promising therapies: ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A. ABO-201, intended for CLN3 disease. ABO-401, developed to treat cystic fibrosis. ABO-50X, aimed at various genetic eye disorders. Additionally, Abeona is advancing AAV-based gene therapy solutions through its proprietary AIM vector platform. The company, which was founded in 1974 and is headquartered in New York, New York, changed its name to Abeona Therapeutics Inc. in June 2015, having previously been known as PlasmaTech Biopharmaceuticals, Inc.
Latest quote
$5.01
−$0.07 · -1.38%
Regular session · ET · Market data may be delayed.
Abeona Therapeutics Inc. is a biopharmaceutical company in the clinical development stage, focused on creating innovative gene and cell therapies to address severe and uncommon genetic diseases. Its leading program, EB-101, an autologous gene-corrected cell therapy, is presently in a Phase III clinical trial for treating recessive dystrophic epidermolysis bullosa. The company's pipeline also features several other promising therapies: ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A. ABO-201, intended for CLN3 disease. ABO-401, developed to treat cystic fibrosis. ABO-50X, aimed at various genetic eye disorders. Additionally, Abeona is advancing AAV-based gene therapy solutions through its proprietary AIM vector platform. The company, which was founded in 1974 and is headquartered in New York, New York, changed its name to Abeona Therapeutics Inc. in June 2015, having previously been known as PlasmaTech Biopharmaceuticals, Inc.
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
51
Fair Value
Sentiment
41
Mixed
Risk
45
Elevated Risk
Momentum
75
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Abeona Therapeutics Inc. is a biopharmaceutical company in the clinical development stage, focused on creating innovative gene and cell therapies to address severe and uncommon genetic diseases. Its leading program, EB-101, an autologous gene-corrected cell therapy, is presently in a Phase III clinical trial for treating recessive dystrophic epidermolysis bullosa. The company's pipeline also features several other promising therapies: ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A. ABO-201, intended for CLN3 disease. ABO-401, developed to treat cystic fibrosis. ABO-50X, aimed at various genetic eye disorders. Additionally, Abeona is advancing AAV-based gene therapy solutions through its proprietary AIM vector platform. The company, which was founded in 1974 and is headquartered in New York, New York, changed its name to Abeona Therapeutics Inc. in June 2015, having previously been known as PlasmaTech Biopharmaceuticals, Inc.
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 5.82M USD | — | 3.5M USD | 1.41M USD | 3M USD |
| Cost of goods sold | 1.53M USD | 2.91M USD | 1.61M USD | 450K USD | — |
| Gross profit | 4.29M USD | −2.91M USD | 1.9M USD | 964K USD | 3M USD |
| Research and development | 26.81M USD | 34.36M USD | 31.09M USD | 28.97M USD | 38.73M USD |
| Selling, general, and administrative | 65.03M USD | 29.85M USD | 19M USD | 17.26M USD | 21.64M USD |
| Operating expenses | 93.74M USD | 61.3M USD | 49.03M USD | 51.88M USD | 92.84M USD |
| Interest income | 5.56M USD | 4.25M USD | 2.12M USD | 431K USD | 40K USD |
| Interest expense | 3.74M USD | 4.21M USD | 418K USD | 736K USD | 3.66M USD |
| Depreciation and amortization | 3.56M USD | 2.91M USD | 3.2M USD | 4.58M USD | 4.46M USD |
| Operating income | −89.45M USD | −64.21M USD | −47.14M USD | −50.92M USD | −89.84M USD |
| Net income | 71.18M USD | −63.73M USD | −54.19M USD | −39.7M USD | −84.94M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
| Action | Ex-dividend date | Details | Record date | Payment date |
|---|---|---|---|---|
Dividend | Mar 31, 2000 | $0.593Irregular | — | — |
Ex-dividend Mar 31, 2000
$0.593
Irregular
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI8.94M0.00%2.3T USD0.03%$379.23-0.47%
iShares Russell 2000 ETFIWM6.14M0.01%78.56B USD0.19%$277.06-0.23%
Vanguard Extended Market ETFVXF3.67M0.00%95.4B USD0.05%$232.79-0.30%
Vanguard Russell 2000 ETFVTWO1.47M0.01%18B USD0.06%$111.9-0.28%
Simplify Propel Opportunities ETFSURI1.4M1.88%74.84M USD2.82%$17.01+0.95%
iShares Micro-Cap ETFIWC733.07K0.06%1.33B USD0.60%$182.39-0.53%
iShares Core S&P Total U.S. Stock Market ETFITOT610.22K0.00%98.16B USD0.03%$168.44-0.50%
WisdomTree U.S. SmallCap FundEES466.89K0.07%683.92M USD0.38%$65.285+0.35%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOSimplify Propel Opportunities ETFSURIiShares Micro-Cap ETFIWCiShares Core S&P Total U.S. Stock Market ETFITOTWisdomTree U.S. SmallCap FundEESAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
